Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by ARGA Investment Management LP

ARGA Investment Management LP boosted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 83.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,195 shares of the specialty pharmaceutical company's stock after buying an additional 5,562 shares during the quarter. ARGA Investment Management LP's holdings in Jazz Pharmaceuticals were worth $1,359,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Versant Capital Management Inc raised its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock worth $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals during the second quarter valued at $29,000. EverSource Wealth Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $33,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. TD Cowen reduced their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research report on Monday, November 18th. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research note on Monday, August 19th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $175.33.

Jazz Pharmaceuticals Stock Down 0.9 %

NASDAQ:JAZZ traded down $1.05 during midday trading on Friday, reaching $121.59. The company had a trading volume of 286,839 shares, compared to its average volume of 711,713. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The firm has a market capitalization of $7.35 billion, a price-to-earnings ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock's fifty day simple moving average is $114.87 and its 200-day simple moving average is $111.13.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company's stock, valued at $1,573,707.30. This represents a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock worth $720,160 over the last 90 days. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.